ArticleCurrent urology2023
Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study.
Article in Current urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Predictive factors of incidental prostate cancer in patients undergoing surgery for presumed benign prostatic hyperplasia: an updated systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study.Radiation oncology (London, England) · 2026Trial
- Observed Versus Expected Use of Diagnostic Imaging and Radiotherapy in Prostate Cancer in the Lazio Region (Italy): An Integrated Population-Based and Literature-Informed Framework for Healthcare Planning.Healthcare (Basel, Switzerland) · 2026Article
- Integrating Prostate-Specific Antigen Density and Prostate Imaging Reporting and Data System Scores to Optimize Detection of Clinically Significant Prostate Cancer: A Multivariable Risk Model Approach.Journal of clinical laboratory analysis · 2026Article
- Fasting blood glucose to HDL-C ratio as a potential biomarker for prostate cancer risk classification.BMC urology · 2026Article
- Real-world Inter-rater Agreement of PI-QUAL Version 2 for Prostate Magnetic Resonance Imaging Quality Assessment and Its Association with Diagnostic Accuracy.European urology open science · 2026Article
- Day surgery mode of multi-modal image AI fusion targeted transperineal biopsy technique using electromagnetic navigation tracking system under local anesthesia.BMC urology · 2026Article
- External Validation of the PROMOD Strategy, Combining PI-RADS Score and PSA Density, to Select Patients for Prostatic Biopsies.Research and reports in urology · 2026Article
- Artificial Intelligence-Assisted Biparametric MRI for Detecting Prostate Cancer-A Comparative Multireader Multicase Accuracy Study.Journal of clinical medicine · 2025Article
- Lesional volume in the prediction of clinically significant prostate cancer.World journal of surgical oncology · 2025Article
- Performance of GPT-4 for automated prostate biopsy decision-making based on mpMRI: a multi-center evidence study.Military Medical Research · 2025Article
- Interpretable machine learning driven biomarker identification and validation for prostate cancer.Translational andrology and urology · 2025Article
- The Correlation Between Body Mass Index and Prostate Volume: A Retrospective Analysis of Pre and Postoperative Measurements in Prostate Cancer Patients.The Prostate · 2025Observational
- Pathologic characteristics and management strategies for two categories of prostate cancer patients with low prostate-specific antigen undergoing radical prostatectomy.Translational andrology and urology · 2025Article
- A retrospective study on predicting clinically significant prostate cancer via a bi-parametric ultrasound-based deep learning radiomics model.Frontiers in oncology · 2025Article
- Interpretable multiparametric MRI radiomics-based machine learning model for preoperative differentiation between benign and malignant prostate masses: a diagnostic, multicenter study.Frontiers in oncology · 2025Article
- Analysis of the Diagnostic Efficacy and Clinical Utility of Multiparametric MRI in Prostate Cancer Diagnosis.Cancer management and research · 2025Article
- Does Size Matter? A Retrospective Study Analysing the Size of PI-RADS 4 Lesions and Its Associated Prostate Cancer Positivity with Transperineal Prostate Biopsy.Research and reports in urology · 2025Article
- Prostate cancer diagnostics: evolution over 30 years and the impact of education level - a prospective population-based study.Frontiers in oncology · 2025Article
- Bridging Knowledge Gaps in Prostate Cancer Screening Among Northern Saudi Males: Implications for Improving Screening Adherence and Early Detection.Patient preference and adherence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the predictive values of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2), prostate-specific antigen (PSA) level, PSA density (PSAD), digital rectal examination findings, and prostate volume, individually and in combination, for the detection of prostate cancer (PCa) in biopsy-naive patients. Methods: We retrospectively analyzed 630 patients who underwent transrectal systematic prostate biopsy following prostate multiparametric magnetic resonance imaging. A standard 12-core biopsy procedure was performed. Univariate and multivariate analyses were performed to determine the significant predictors of clinically significant cancer but not PCa. Results: The median age, PSA level, and PSAD were 70 years, 8.6 ng/mL, and 0.18 ng/mL/mL, respectively. A total of 374 (59.4%) of 630 patients were biopsy-positive for PCa, and 241 (64.4%) of 374 were diagnosed with clinically significant PCa (csPCa). The PI-RADS v2 score and PSAD were independent predictors of PCa and csPCa. The PI-RADS v2 score of 5 regardless of the PSAD value, or PI-RADS v2 score of 4 plus a PSAD of <0.3 ng/mL/mL, was associated with the highest csPCa detection rate (36.1%-82.1%). Instead, the PI-RADS v2 score of <3 and PSAD of <0.3 ng/mL/mL yielded the lowest risk of csPCa. Conclusion: The combination of the PI-RADS v2 score and PSAD could prove to be a helpful and reliable diagnostic tool before performing prostate biopsies. Patients with a PI-RADS v2 score of <3 and PSAD of <0.3 ng/mL/mL could potentially avoid a prostate biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.